Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs ABNG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–2 Matrix Metrics)

TLPH Overall Winner 6-Pillar Tally: TLPH 3 – 1 ABNG (2 Tie) Matrix Metrics: TLPH 8 – 2 ABNG

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over ABNG (ABNG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ABNG carries 53.0/100 (HOLD) at $20.21 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While ABNG currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs ABNG
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
ABNG US Equity
ABNG
Institutional Equity
$20.21
+8.39% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.34β · 71% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $18.56 · SMA50: $17.34

6-Pillar Scorecard Institutional Category Breakdown (TLPH 3 – 1 ABNG)

Columns: Metric · TLPH · ABNG
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TLPH
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $1,000 N/A
Market Cap $53.7M N/A
3. Profitability & Quality TLPH
Gross Margin N/A N/A
Operating Margin -1474700.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -143.4% N/A
4. Balance Sheet & Cash Flow ABNG
Cash Generation (TTM) -$15M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 118.4% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (8) vs ABNG (2)
Institutional Metric TLPH ABNG Criterion Row Edge
Market Capitalization
Scale
$53.7M N/A Larger Scale TLPH
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth TLPH
Operating Margin (TTM)
Profitability
-1474700.0% N/A Higher Margin TLPH
Net Profit Margin
Profitability
0.0% N/A Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-143.4% N/A Higher ROE TLPH
52-Week Range Position
Momentum
20% ($1–$2) 100% ($13–$20) Stronger Trend ABNG
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 2.34β · 71% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 53.0 / 100 (HOLD) Higher Composite ABNG
Trailing 12M Revenue (USD)
Operating Scale
$1,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +17.48 pp
TLPH: +26.21% · ABNG: +8.73%
3M Horizon TLPH +64.33 pp
TLPH: +75.91% · ABNG: +11.58%
6M Horizon TLPH +13.37 pp
TLPH: +30.0% · ABNG: +16.63%
1Y Horizon ABNG +46.83 pp
TLPH: -1.52% · ABNG: +45.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs ABNG. Trailing 12-month operating profitability (TLPH -1474700.0% vs ABNG N/A) and valuation multiples (TLPH 1.0x vs ABNG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
ABNG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABNG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABNG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABNG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs ABNG Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over ABNG (ABNG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas ABNG carries 53.0/100 (HOLD) at $20.21 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While ABNG currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with ABNG at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus N/A for ABNG. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABNG.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ABNG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus ABNG (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, ABNG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.34β · 71% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.